Celyad SA (CYAD)
| Previous close | 1.3900 |
| Open | 1.4500 |
| Bid | 1.3700 x 1000 |
| Ask | 1.4500 x 900 |
| Day's range | 1.4000 - 1.4500 |
| 52-week range | 1.2400 - 5.3200 |
| Volume | |
| Avg. volume | 139,390 |
| Market cap | 33.628M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5070 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.08 |
- Business Wire
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium, September 20, 2022--Regulatory News: Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufa
- Business Wire
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
MONT-SAINT-GUIBERT, Belgium, August 05, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the first half ended June 30, 2022.
- Business Wire
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
MONT-SAINT-GUIBERT, Belgium, August 01, 2022--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the Company made changes to the eligibility criteria
